Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 16/20 | 0.60 |
| ▸ | ABL1 | P00519 | 6/20 | 0.60 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.57 |
| ▸ | YES1 | P07947 | 1/20 | 0.57 |
| ▸ | KDR | P35968 | 1/20 | 0.57 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | HCK | P08631 | 1/20 | 0.46 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.46 |
| ▸ | BRAF | P15056 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL230386 | 0.93 | SRC (0.56) | SRCABL1PDGFRBYES1KDR | |
| SCHEMBL231132 | 0.90 | ALK (0.58) | SRCABL1PDGFRBYES1KDR | |
| SCHEMBL230383 | 0.89 | SRC (0.54) | SRCABL1PDGFRBYES1KDR | |
| SCHEMBL2579072 | 0.83 | SRC (0.52) | SRCABL1PDGFRBYES1KDR | |
| SCHEMBL612493 | 0.77 | TTK (0.53) | SRCABL1PDGFRBYES1KDR | |
| SCHEMBL230101 | 0.76 | BRAF (0.50) | SRCALKBRAF | |
| SCHEMBL4267397 | 0.75 | SRC (1.00) | SRCABL1PDGFRBYES1KDR | |
| SCHEMBL226225 | 0.74 | SRC (0.55) | SRCABL1PDGFRBYES1KDR | |
| SCHEMBL2580732 | 0.73 | SRC (0.55) | SRCABL1PDGFRBYES1KDR | |
| SCHEMBL4264015 | 0.73 | SRC (1.00) | SRCABL1PDGFRBYES1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389530-B2 | Substituted quinazoline compounds | FOVEA PHARMACEUTICALS (FR) | 2013-03-05 | — | — | US | claimed |
| US-20120004210-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS | FOVEA PHARMACEUTICALS SA | 2012-01-05 | — | — | US | claimed |
| US-8389530-B2 | Substituted quinazoline compounds | FOVEA PHARMACEUTICALS (FR) | 2013-03-05 | — | — | US | disclosed |
| US-20120004210-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS | FOVEA PHARMACEUTICALS SA | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004210-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS | MAP3K5, MAP3K1, MAP3K2 | SRC 1325/4885ABL1 442/4885PDGFRB 1013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.